Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of parkinsons disease

Chemical Research in Toxicology

Volumn 27, Issue 8, 2014, Pages 1359-1361

  Casida, John E ^a   Ford, Breanna ^a   Jinsmaa, Yunden ^b   Sullivan, Patti ^b   Cooney, Adele ^b   Goldstein, David S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETALDEHYDE; ACETALDEHYDE; ALDEHYDE DEHYDROGENASE; ALDEHYDE DERIVATIVE; BENOMYL; CATECHOL DERIVATIVE; UNCLASSIFIED DRUG; 3,4 DIHYDROXYPHENYLACETIC ACID; 3,4-DIHYDROXYPHENYLACETALDEHYDE; 4-HYDROXY-2-NONENAL; ALDEHYDE; ANTIFUNGAL AGENT; ENZYME INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME INHIBITION; FIBROBLAST; GLIA CELL; HUMAN; HUMAN CELL; HYPOTHESIS; MOUSE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; DRUG EFFECTS; GENETICS; LIPID PEROXIDATION; METABOLISM; PC12 CELL LINE; RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ALDEHYDE DEHYDROGENASE; ALDEHYDES; ANIMALS; ANTIFUNGAL AGENTS; BENOMYL; CELL LINE; ENZYME INHIBITORS; HUMANS; LIPID PEROXIDATION; MICE; PARKINSON DISEASE; PC12 CELLS; RATS;

EID: 84906258161     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx5002223     Document Type: Article

References (23)

1. Di Monte, D. A. (2003) The environment and Parkinsons disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol. 2, 531-538
2. Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., and Greenamyre, J. T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinsons disease Nat. Neurosci. 3, 1301-1306
3. Tanner, C. M., Kamel, F., Ross, G. W., Hoppin, J. A., Goldman, S. M., Korell, M., Marras, C., Bhudhikanok, G. S., Kasten, M., Chade, A. R., Comyns, K., Richards, M. B., Meng, C., Priestly, B., Fernandez, H. H., Cambi, F., Umbach, D. M., Blair, A., Sandler, D. P., and Langston, J. W. (2011) Rotenone, paraquat, and Parkinsons disease Environ. Health Perspect. 119, 866-872
4. Fitzmaurice, A. G., Rhodes, S. L., Lulla, A., Murphy, N. P., Lam, H. A., ODonnell, K. C., Barnhill, L., Casida, J. E., Cockburn, M., Sagasti, A., Stahl, M. C., Maidment, N. T., Ritz, B., and Bronstein, J. M. (2013) Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease Proc. Natl. Acad. Sci. U.S.A. 110, 636-641
5. Fitzmaurice, A. G., Rhodes, S. L., Cockburn, M., Ritz, B., and Bronstein, J. M. (2014) Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson disease Neurology 82, 419-426
6. Staub, R. E., Quistad, G. B., and Casida, J. E. (1998) Mechanism for benomyl action as a mitochondrial aldehyde dehydrogenase inhibitor in mice Chem. Res. Toxicol. 11, 535-543
7. Staub, R. E., Quistad, G. B., and Casida, J. E. (1999) S -Methyl N -butylthiocarbamate sulfoxide. Selective carbamoylating agent for mouse mitochondrial aldehyde dehydrogenase Biochem. Pharmacol. 58, 1467-1473
8. Burke, W. J., Li, S. W., Williams, E. A., Nonneman, R., and Zahm, D. S. (2003) 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinsons disease pathogenesis Brain Res. 989, 205-213
9. Rees, J. N., Florang, V. R., Eckert, L. L., and Doorn, J. A. (2009) Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol Chem. Res. Toxicol. 22, 1256-1263
10. Panneton, W. M., Kumar, V. B., Gan, Q., Burke, W. J., and Galvin, J. E. (2010) The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis PLoS One 5, e15251
11. Anderson, D. G., Santhana Mariappan, S. V., Buettner, G. R., and Doorn, J. A. (2011) Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho -quinone J. Biol. Chem. 286, 26978-26986
12. Goldstein, D. S., Sullivan, P., Holmes, C., Kopin, I. J., Basile, M. J., and Mash, D. C. (2011) Catechols in post-mortem brain of patients with Parkinson disease Eur. J. Neurol. 18, 703-710
13. Goldstein, D. S., Sullivan, P., Cooney, A., Jinsmaa, Y., Sullivan, R., Gross, D. J., Holmes, C., Kopin, I. J., and Sharabi, Y. (2012) Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinsons disease J. Neurochem. 123, 932-943
14. Holmes, C., Eisenhofer, G., and Goldstein, D. S. (1994) Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection J. Chromatogr. B: Biomed. Sci. Appl. 653, 131-138
15. Goldstein, D. S., Sullivan, P., Holmes, C., Miller, G. W., Alter, S., Strong, R., Mash, D. C., Kopin, I. J., and Sharabi, Y. (2013) Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinsons disease J. Neurochem. 126, 591-603
16. Wey, M.C.-Y., Fernandez, E., Martinez, P. A., Sullivan, P., Goldstein, D. S., and Strong, R. (2012) Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinsons disease PLoS One 7, e31522
17. Lamensdorf, I., Eisenhofer, G., Harvey-White, J., Hayakawa, Y., Kirk, K., and Kopin, I. J. (2000) Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde J. Neurosci. Res. 60, 552-558
18. Ohsawa, I., Nishimaki, K., Yasuda, C., Kamino, K., and Ohta, S. (2003) Deficiency in a mitochondrial aldehyde dehydrogenase increases vulnerability to oxidative stress in PC12 cells J. Neurochem. 84, 1110-1117
19. Marchitti, S. A., Deitrich, R. A., and Vasiliou, V. (2007) Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase Pharmacol. Rev. 59, 125-150
20. Koppaka, V., Thompson, D. C., Chen, Y., Ellermann, M., Nicolaou, K. C., Juvonen, R. O., Petersen, D., Deitrich, R. A., Hurley, T. D., and Vasiliou, V. (2012) Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application Pharmacol. Rev. 64, 520-539
21. Leiphon, L. T. and Picklo, M. J., Sr. (2007) Inhibition of aldehyde detoxification in CNS mitochondria by fungicides Neurotoxicology 28, 143-149
22. Doorn, J. A., Hurley, T. D., and Peterson, D. R. (2006) Inhibition of human mitochondrial aldehyde dehydrogenase by 4-hydroxynon-2-enal and 4-oxonon-2-enal Chem. Res. Toxicol. 19, 102-110
23. Jinsmaa, Y., Florang, V. R., Rees, J. N., Anderson, D. G., Strack, S., and Doorn, J. A. (2009) Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate Chem. Res. Toxicol. 22, 835-841